论文部分内容阅读
目的探讨吡柔比星膀胱内灌注预防浅表性膀胱癌术后复发的临床疗效。方法89例浅表性膀胱癌患者于手术后1周内开始行吡柔比星膀胱灌注,每次30mg,每周1次,共8次,以后每月1次,连用10个月,总疗程12个月。结果术后平均随访时间(13.4±4.3)个月。肿瘤复发15例,复发率为16.8%。结论吡柔比星膀胱灌注预防浅表性膀胱癌术后复发效果明确,疗效满意,患者耐受性好,是较理想的膀胱灌注化疗药物。
Objective To investigate the clinical efficacy of intravesical instillation of pirarubicin in preventing postoperative recurrence of superficial bladder cancer. Methods Eighty-nine patients with superficial bladder cancer underwent intravesical instillation of pirarubicin at a dose of 30mg once a week for 8 weeks, once a month for 10 months. The total course of treatment 12 months. Results The mean follow-up time was (13.4 ± 4.3) months. Tumor recurrence in 15 cases, the recurrence rate was 16.8%. Conclusion Intravesical instillation of pirarubicin can prevent postoperative recurrence of superficial bladder cancer with definite effect, satisfactory efficacy and good patient tolerance. It is an ideal intravesical chemotherapy for bladder cancer.